<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-100507</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Antibiotheraphy in the 21st century, antibacterials for the second decade. Posibilities or realities in the future?</dc:title>
<dc:description xml:lang="en">A review of some antibacterial products is done motivated by the serious situation arisen by the antimicrobial resistance in bacteria. The attention is focus on those drugs with suitable antimicrobial properties that have prospects to be commercialized in the next years because of they are undergoing a clinical development phase (I, II, III). The search for these antibacterial products has been done by an exhaustive study of conference proceedings and web pages of international congresses on chemotherapy, infectious diseases and new antimicrobial drugs. Some of the new antibacterial products acts on known targets, and they belong to already used families. Furthermore, the great majority acts against the gram-positive bacterium. There is also some limited-spectrum antimicrobial drug whose use would minimize the adverse biological effects(AU)</dc:description>
<dc:creator>Martín-del-Rey, Ángel</dc:creator>
<dc:creator>García-Sánchez, Enrique</dc:creator>
<dc:creator>García-Merino, Enrique</dc:creator>
<dc:creator>García-Sánchez, José Elías</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Ante la grave situación planteada por la resistencia de las bacterias a los antibióticos se revisan antibacterianos que por sus propiedades antimicrobianas y por encontrarse en registro o en fase de desarrollo clínico (I, II, III) tienen posibilidades de ser comercializados en años venideros. Su búsqueda se ha realizado investigando en los resúmenes de los libros de actas y páginas web de congresos internacionales de quimioterapia, enfermedades infecciosas y nuevos fármacos. Muchos de los nuevos antibacterianos actúan sobre dianas conocidas y pertenecen a familias ya utilizadas en clínica. La mayor parte actúa sobre grampositivos. Hay alguna sustancia con espectro muy reducido cuya posible utilización minimizaría los efectos biológicos adversos(AU)</dc:description>
<dc:source>Rev Esp Quimioter;25(2): 100-121, jun.2012. ilus</dc:source>
<dc:identifier>ibc-100507</dc:identifier>
<dc:title xml:lang="es">Antibioterapia para el siglo XXI, antibacterianos para la segunda década. ¿Posibilidades o realidades en un futuro?</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d22165^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d626^s22073</dc:subject>
<dc:subject>^d28118^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d2547^s22073</dc:subject>
<dc:subject>^d23258^s22073</dc:subject>
<dc:subject>^d31904^s22073</dc:subject>
<dc:subject>^d54178^s22079</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d911^s22044</dc:subject>
<dc:subject>^d911^s22078</dc:subject>
<dc:subject>^d911^s22079</dc:subject>
<dc:subject>^d2547^s22079</dc:subject>
<dc:subject>^d54178^s22073</dc:subject>
<dc:subject>^d911^s22073</dc:subject>
<dc:subject>^d35322^s22073</dc:subject>
<dc:subject>^d38663^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201206</dc:date>
</metadata>
</record>
</ibecs-document>
